What should be recycled: An integrated model for product recycling desirability

This research was focused on developing a new scientific approach for prioritising recycling of end-of-life products in a circular economy. To date, product complexity based on the mixture of materials has been used as a predictor of what gets recycled. While the separation of materials that make up a product has been modelled as a measure of product complexity, this does not taken into account the benefits and considerations in recycling products. In this paper, a new agenda and approach to prioritise the recycling of products was developed based on a recycling desirability index. The material mixing complexity measure was inverted into a simplicity index and then extended by modelling the security index for the mix of materials and the technological readiness level of recycling technologies. The extended model is proposed as an integrated measure of the desirability of recycling end-of-life products. From this analysis, an apparent recycling desirability boundary, enabling products to be prioritised for recycling, was developed. This model and analysis can be used as an information source in developing policies and product recycling priorities

Arterial Thrombosis in Patients with Cancer

Cancer is a common cause of morbidity and mortality in the USA. While the association between venous thrombosis and malignancy is well established, arterial thrombosis has more recently been recognized as a serious complication of cancer and certain chemotherapeutic agents. This review aims to summarize the most recent literature regarding the incidence and risk factors for cancer-related arterial thrombosis, understand the pathophysiologic mechanisms of thrombosis, and highlight the specific diagnostic and treatment considerations relevant to cancer patients.Based on a recent study looking at the Surveillance, Epidemiology, and End Results (SEER) database, the incidence of arterial thromboembolic events (ATEs) in patients with cancer at 6 months is 4.7%; the presence of an ATE is predictive of worse outcomes. Certain drugs such as platinum-based agents, vascular endothelial growth factor inhibitors, tyrosine kinase inhibitors, and taxanes have been associated with high rates of ATEs. Increased platelet reactivity appears crucial to development of arterial thrombosis in cancer patients. Cancer patients have an increased risk of arterial thrombosis that is likely due to both a cancer-associated procoagulant state as well as the adverse effects of certain chemotherapeutic agents. Treatment of arterial thromboembolism in cancer patients typically requires a multidisciplinary approach in part due to high rates of thrombocytopenia and stent thrombosis in the setting of percutaneous interventions. More studies are needed to investigate optimal prophylaxis, surveillance strategies, and treatments of cancer-related arterial thromboembolic disease